Fulcrum Therapeutics, Inc. (FULC) research
Fulcrum Therapeutics, Inc.- Sector
- Pharmaceuticals
- Last price
- $3.80
- As of
Fulcrum Therapeutics, Inc. (FULC): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-17.
As of . Source: SEC EDGAR filings for FULC. Method and limitations.
Share the FULC intelligence card
See FULC live in the terminal
Track FULC's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live FULC terminal, freeActive signals for FULC
- highCONSENSUS_BUY
7 tracked funds increased FULC this 2026Q2, institutional consensus
- highCONSENSUS_BUY
5 tracked funds increased FULC this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 69% of FULC (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +317% to FULC (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +12016% to FULC (2026Q2)
FREE, NO ACCOUNT
Every signal on FULC, as it fires
You are seeing 5 of 38 signals recorded on FULC since 2026-05-26.
The five above landed across 2 days. The other 33 were recorded on 3 other days. 31 of the 38 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in FULC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 359616109 · 2026Q2 | $11.1M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 359616109 · 2026Q2 | $9.9M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 359616109 · 2026Q2 | $6M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 359616109 · 2026Q2 | $5.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 359616109 · 2026Q2 | $3M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 359616109 · 2026Q2 | $2.4M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, FULC
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
FULC against its peers
FULC's return on equity of -21.5% ranks in the 48th percentile of 21 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | FULC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 403M USD | 5 | 19 |
| Gross margin | n/a | 59.3% | n/a | 5 |
| Operating margin | n/a | 10.6% | n/a | 18 |
| Net margin | n/a | 0.6% | n/a | 18 |
| Return on equity | -21.5% | -9.3% | 48 | 21 |
| P / E | n/a | 13.4x | n/a | 9 |
Peers (24): BIOA, SIGA, AVIR, COLL, ACRS, ESPR, PCRX, AMPH, ALMS, PLRX, ANRO, OMER, PAHC, XERS, INVA, ANIP, NUVB, TRVI, BHC, OCUL, NKTR, SUPN, HRMY, GPCR. Left out: ACB (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (FULC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more FULC signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to FULCand get the insider, 13F, options, and confluence read in one view.